Immunogenicity and Safety of the CoronaVac Vacccine in Patients With Autoimmune Rheumatic Diseases and People Living With HIV/AIDS

42566621.0.0000.0068

Patients with chronic rheumatic diseases (such as systemic lupus erythematosus \[SLE\], rheumatoid arthritis \[RA\], ankylosing spondylitis \[AS\], juvenile idiopathic arthritis \[JIA\], poly/dermatomyositis \[PM/DM\], systemic sclerosis \[SSc\], systemic vasculitis, and primary Sjögren's syndrome \[pSS\]) are particularly susceptible to infectious diseases due to autoimmune disorder itself and its treatment (immunosuppressive therapies). Similarly, people living with HIV/AIDS (PLWHA) are predisposed to infections by different agents. The current 2019 Coronavirus Disease Pandemic-19 (COVID-19), caused by the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) began in December 2019 in Wuhan, China, and quickly became a global health and economic emergency by taking to an unprecedented burden on health systems around the world. However, SARS-Cov-2 infection raised particular concern in patients with autoimmune rheumatic diseases (DRAI) since, due to chronic inflammatory immune dysregulation and the regular use of immunosuppressive drugs, these patients are considered to be at high risk of contracting SARS-CoV-2 and potentially evolving to a worse prognosis. The overlap between the COVID-19 pandemic and the HIV/AIDS pandemic also poses an additional challenge, as the impact of co-infection is not yet fully known. The response to vaccines for other agents, however, has already been described as compromised in PLWHA. Vaccination is the most effective preventive measure to control the spread of coronavirus and to reduce associated complications. Usually, live or attenuated vaccines are not recommended for patients with chronic rheumatic diseases using immunosuppressants. However, immunization with inactivated agents is strongly indicated, resulting, in general, in good immunogenicity and adequate vaccine safety, as well as without relevant deleterious effects on diseases. Vaccine efficacy studies are needed to verify the immunogenicity of the vaccine against COVID-19 in immunosuppressed patients with rheumatological disease and those with HIV-related disease considering the risk of greater severity. In addition, it is important to assess the safety of the vaccine in this population as well as the possibility of reactivating the rheumatological disease itself. The present study will evaluate the safety and immunogenicity of the CoronaVac (Coronavirus vaccine, Sinovac Biotech Ltd.) in patients with rheumatic diseases and PLWHA

2021-02-09

2023-11-27

2024-03-22

Completed

Early phase I

2196

Inclusion Criteria: * RA patients according to the classification criteria of the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR). * Patients with axial spondyloarthritis (ASAS criteria 2009) and psoriatic arthritis (CASPAR 2012 criteria). * SLE patients according to the SLICC classification criteria. * SSc patients according to the ACR preliminary criteria. * Patients with inflammatory myopathies according to the Bohan and Peter's criteria. * Patients with primary vasculitis. * Patients with pSS (2002 American-European Consensus group criteria and/or 2016 classification criteria of the EULAR/ACR. * Patients with primary APS (primary antiphospholipid syndrome) (Sydney classification criteria). * Patients with HIV-related illness. Exclusion Criteria: * History of anaphylactic response to vaccine components. * Acute febrile illness. * Guillain-Barré syndrome, decompensated heart failure (class III or IV), demyelinating disease. * History of live virus vaccine up to 4 weeks before, virus vaccine inactivated up to 2 weeks before. * History of having received blood products up to 6 months before the study. * Individuals who do not accept to participate in the study and/or whose guardians do not agree to participate in the study. * Hospitalized patients. * Patients with severe conditions requiring hospitalization.

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Study consisting of 3 arms, all of which will receive CoronaVac: patients with rheumatic diseases, PLWHA, and healthy controls. Also, in an exploratory, post hoc, substudy nested within the trial, 2 other arms will receive exercise or no intervention 1 hoour before the third dose.', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 2196, 'type': 'ACTUAL'}}

2024-03-26